# Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

> **NCT05810740** · PHASE1 · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 37 (actual)

## Conditions studied

- Melanoma
- BRAF V600 Mutation
- Unresectable Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** Binimetinib 15 MG
- **DRUG:** Binimetinib 45 MG

## Key facts

- **NCT ID:** NCT05810740
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-31
- **Primary completion:** 2022-12-22
- **Final completion:** 2023-01-18
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810740, "Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05810740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*